Clinical Trial: Serum Biomarkers in Diagnosis and Predicting Prognosis of Endometrial and Ovarian Cancers

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Observational [Patient Registry]

Official Title: Value of TFF3, SFRP4, Romo1 and NFKB as Serum Biomarkers in Diagnosis and Predicting Prognosis of Endometrial and Ovarian Cancers

Brief Summary: This study evaluates the usefulness of serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB as potential diagnostic and prognostic biomarkers in endometrial and ovarian carcinoma.

Detailed Summary:
Sponsor: Ilker Kahramanoglu

Current Primary Outcome: Efficacy of serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-Κb in discrimination of benign and malignant gynecologic disease [ Time Frame: 2 days ]

To measure serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB between groups and to identify a possible significant diagnostic marker


Original Primary Outcome: Same as current

Current Secondary Outcome: Efficacy of serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-Κb in predicting overall survival and disease-free survival [ Time Frame: 1 year ]

To determine any relationship between prognosis of endometrial and ovarian cancer and serum levels of four different biomarkers


Original Secondary Outcome: Same as current

Information By: Istanbul University

Dates:
Date Received: April 4, 2017
Date Started: April 4, 2017
Date Completion: April 2018
Last Updated: April 7, 2017
Last Verified: April 2017